PT - JOURNAL ARTICLE AU - Paramo, Marina Viñeta AU - Abu-Raya, Bahaa AU - Reicherz, Frederic AU - Xu, Rui Yang AU - Bone, Jeffrey N. AU - Srigley, Jocelyn A. AU - Solimano, Alfonso AU - Goldfarb, David M. AU - Skowronski, Danuta M. AU - Lavoie, Pascal M. TI - Comparative analysis of pediatric Respiratory Syncytial Virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada AID - 10.1101/2022.11.18.22282477 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.18.22282477 4099 - http://medrxiv.org/content/early/2022/11/19/2022.11.18.22282477.short 4100 - http://medrxiv.org/content/early/2022/11/19/2022.11.18.22282477.full AB - Background The COVID-19 pandemic affected Respiratory Syncytial Virus (RSV) circulation and surveillance, causing logistical complexity for health systems. Our objective was to describe changes in epidemiology and clinical severity of RSV cases in British Columbia, Canada.Methods Comparative analysis of RSV detections in children <36 months at BC Children’s Hospital (BCCH) between September 1 and August 31 of 2017-18, 2018-19, 2019-20, 2020-21 and 2021-22.Results About one-fifth of children tested RSV positive on average across all periods. The median age of RSV cases was 11.8 [IQR: 3.8–22.3] months in 2021-22 versus 6.3 [IQR: 1.9–16.7] months in 2017-20 (p<0.001). Increased testing in 2021-22 (n=3,120) compared to 2017-20 (average n=1,222/period) detected milder infections with lower proportion hospitalized in all age subgroups <6 (26.0%), 6-11 (12.3%), 12-23 (12.2%) and 24-35 (16.0%) months versus 2017-20 (49.3%, 53.5%, 62.6%, 57.5%, respectively) (all p<0.001). Children <6 months consistently comprised most hospitalizations and those born prematurely <29 weeks or with chronic respiratory co-morbidities remained at highest hospitalization risk in 2021-22. Among hospitalized cases, intensive care, respiratory support or supplemental oxygen use did not differ between the 2017-20 and 2021-22 periods.Conclusions RSV circulation halted during the pandemic, but with the lifting of mitigation measures a subsequent resurgence in children <36 months of age was accompanied by shift toward older (24-35 month) cases in 2021-22, without increased severity. For the 2022-23 period, increased circulation and residual vulnerability in additional birth cohorts spared from RSV infection during the pandemic could have marked cumulative healthcare impact, even without increase in proportion hospitalized.Competing Interest StatementPML received nominal payments from Sanofi, but no matter directly relevant to this study. Other authors have no conflicts of interest to declare.Funding StatementThis study was funded by the Government of Canada via its COVID-19 Immunity Task Force. PML is an employee of Provincial Health Authority Services of British Columbia who also received a portion of salary support, from the British Columbia Children's Hospital Foundation, through the Investigator Grant Award Program. BAR received a post-doctoral award from Michael Smith Health Research British Columbia. FR was funded by the (German Research Foundation (Deutsche Forschungsgemeinschaft) - RE 4598/1-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of British Columbia Children's & Women's Research Ethics Board (approval number H11-03424).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.